Genmab announced its acquisition of Dutch biotech Merus for approximately $8 billion in cash, securing rights to Merus’ bispecific antibody petosemtamab in late-stage development for head and neck cancer. The deal marks Genmab's strategic shift from royalty-based partnerships to fully owning and commercializing promising oncology assets. Petosemtamab, in pivotal Phase 3 trials, has demonstrated potential survival benefits when combined with Merck's Keytruda immunotherapy. Market analysts anticipate multibillion-dollar sales upon approval, potentially slated for 2027, signaling a major step forward in Genmab’s oncology portfolio expansion.